Clinical Trial: Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 and Agalsidase in Subjects With Fabry Disease.
Brief Summary: The purpose of this study is to determine the effects of AT1001 on the safety of agalsidase, and the effects of agalsidase on the safety of AT1001.
Detailed Summary:
Sponsor: Amicus Therapeutics
Current Primary Outcome: Plasma pharmacokinetics [ Time Frame: Over 24-hour period after dosing ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Amicus Therapeutics
Dates:
Date Received: September 7, 2010
Date Started: February 2011
Date Completion:
Last Updated: December 19, 2013
Last Verified: December 2013